Roy O Weller, Cohen Nicola R, Nicoll James A R
Clinical Neurosciences, Mailpoint 813, Southampton General Hospital, Southampton, SO16 6YD, UK.
Indian J Pathol Microbiol. 2005 Jul;48(3):289-99.
Dementia is characterized clinically by progressive cognitive decline, often with impairment of memory. The pathology of dementias is either focal as with infarcts in Vascular Dementia or diffuse as typified by Alzheimer's disease. In many cases of Alzheimer's disease there is a mixture of focal infarcts and diffuse changes. Diffuse pathology in dementias comprises mainly intracellular and extracellular protein deposits. Intracellular inclusions are of tau protein (Alzheimer's disease; and some frontotemporal dementias), alpha-synuclein (Dementia with Lewy bodies) and huntingtin (Huntington's disease). Soluble and insoluble peptides also accumulate in the extracellular spaces of brain parenchyma in dementias with diffuse pathology, mainly amyloid-beta (Abeta) in parenchymal plaques and in artery walls as cerebral amyloid angiopathy (Alzheimer's disease and Dementia with Lewy bodies). Insoluble prion protein (PrP) is deposited in brain parenchyma in Creutzfeldt-Jakob disease and other insoluble amyloid peptides accumulate in brain and vessel walls infamilial dementias. The pattern of extracellular deposits in brain and artery walls suggests that there is a failure of elimination of peptides, such as Abeta along perivascular interstitial fluid drainage pathways ("lymphatics") from the aged brain and in Alzheimer's disease. Such failure may be due to reduced pulsations as arteries stiffen with age and cerebrovascular disease. Immunization against Abeta removes insoluble deposits of Abeta from brain parenchyma and may allow improved clearance of soluble Abeta. Reducing cerebrovascular disease and facilitating elimination of Abeta along perivascular drainage routes may offer long-term preventative measuresfor both Vascular Dementia and for Alzheimer's disease.
痴呆症在临床上的特征是进行性认知衰退,常伴有记忆力损害。痴呆症的病理变化要么是局灶性的,如血管性痴呆中的梗死;要么是弥漫性的,如阿尔茨海默病。在许多阿尔茨海默病病例中,存在局灶性梗死和弥漫性变化的混合情况。痴呆症中的弥漫性病理变化主要包括细胞内和细胞外蛋白质沉积。细胞内包涵体有tau蛋白(阿尔茨海默病;以及一些额颞叶痴呆)、α-突触核蛋白(路易体痴呆)和亨廷顿蛋白(亨廷顿舞蹈病)。在具有弥漫性病理变化的痴呆症中,可溶性和不溶性肽也在脑实质的细胞外间隙中积聚,主要是脑实质斑块和动脉壁中的淀粉样β蛋白(Aβ),如脑淀粉样血管病(阿尔茨海默病和路易体痴呆)。不溶性朊蛋白(PrP)在克雅氏病的脑实质中沉积,其他不溶性淀粉样肽在家族性痴呆的脑和血管壁中积聚。脑和动脉壁中细胞外沉积物的模式表明,从老年大脑以及阿尔茨海默病患者的大脑中通过血管周围间质液引流途径(“淋巴管”)清除肽,如Aβ的过程出现了障碍。这种障碍可能是由于随着年龄增长和脑血管疾病,动脉变硬导致搏动减少所致。针对Aβ的免疫接种可清除脑实质中不溶性Aβ沉积物,并可能改善可溶性Aβ的清除。减少脑血管疾病并促进Aβ沿血管周围引流途径的清除,可能为血管性痴呆和阿尔茨海默病提供长期预防措施。